ACMCX | ANMCX | ACMCX / ANMCX | |
Total Expense Ratio | 1.51 | 1.50 | 101% |
Annual Report Gross Expense Ratio | 1.51 | 1.50 | 101% |
Fund Existence | 23 years | 23 years | - |
Gain YTD | -0.475 | -0.513 | 93% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 2500 | 2500 | 100% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 1.03B | 1.25B | 82% |
Annual Yield % from dividends | 2.01 | 1.78 | 113% |
Returns for 1 year | 0.89 | 0.86 | 104% |
Returns for 3 years | 6.20 | 5.46 | 113% |
Returns for 5 years | 3.92 | 4.48 | 88% |
Returns for 10 years | 4.64 | 4.09 | 113% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
COSNX | 11.32 | 0.10 | +0.89% |
Columbia Overseas Core Institutional | |||
BRBCX | 14.20 | 0.03 | +0.21% |
BlackRock Tactical Opportunities Inv C | |||
RNGHX | 59.44 | -0.06 | -0.10% |
American Funds New Economy R5E | |||
MSCOX | 9.23 | -0.06 | -0.65% |
Morgan Stanley Inst Inception C | |||
RYBOX | 49.98 | -1.02 | -2.00% |
Rydex Biotechnology A |